Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
Xuan GeCarolyn E BehrendtSusan E YostNiki PatelRaynald SamoaDaphne StewartMina S SedrakSayeh LavasaniJames WaismanYuan YuanJoanne MortimerPublished in: The oncologist (2023)
While receiving alpelisib, patients of Asian ancestry, as well as patients with pre-existing hyperglycemia and/or BMI above 20, should be closely monitored for hyperglycemia. The mechanism underlying the current association of alpelisib-associated hyperglycemia with Asian ancestry is independent of BMI and merits further study. The high incidence of hyperglycemia resulted in a change in practice to include consultation with a diabetes nurse educator or endocrinologist at the start of alpelisib.
Keyphrases
- metastatic breast cancer
- diabetic rats
- end stage renal disease
- primary care
- body mass index
- type diabetes
- cardiovascular disease
- ejection fraction
- chronic kidney disease
- healthcare
- palliative care
- risk factors
- peritoneal dialysis
- metabolic syndrome
- physical activity
- quality improvement
- weight loss
- glycemic control
- insulin resistance